VIP

Vaccines and Imaging Partnership

Coordinatore	UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK    more  Organization address address: Western Road city: CORK postcode: - contact info Titolo: Dr. Nome: David Cognome: O'connell Email: send email Telefono: 353214000000
Nazionalità Coordinatore	Ireland [IE]
Totale costo	1˙287˙900 €
EC contributo	1˙287˙900 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2013-IAPP
Funding Scheme	MC-IAPP
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-10-01   -   2018-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK  Organization address address: Western Road city: CORK postcode: - contact info Titolo: Dr. Nome: David Cognome: O'connell Email: send email Telefono: 353214000000	IE (CORK)	coordinator	623˙601.28
2	GLAXOSMITHKLINE VACCINES SRL  Organization address address: Via Fiorentina 1 city: SIENA postcode: 53100 contact info Titolo: Dr. Nome: Francesco Cognome: Gulli Email: send email Telefono: +39 0577 243390 Fax: +39 0577 243085	IT (SIENA)	participant	444˙112.15
3	ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE  Organization address address: BATIMENT CE 3316 STATION 1 city: LAUSANNE postcode: 1015 contact info Titolo: Prof. Nome: Elena Cognome: Dubikovskaya Email: send email Telefono: +41 21693 9304	CH (LAUSANNE)	participant	220˙186.64

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'There exists an urgent need to advance methods for detection of bacteria in the body, primarily in the context of infectious disease research. Real-time in vivo analysis empowers the investigator with the ability to non-invasively assess bacterial activity over time, as well as host responses to infection and interventions. Optical Imaging (OI) modalities are based on the detection and quantification of bioluminescent or fluorescent light from the subject and represent powerful yet cost-efficient and convenient systems. By labelling of bacteria and/or host cells of interest, both bacterial and host responses can be assessed in rapid, high-throughput analyses, providing spatial, temporal and quantitative read-out, without the need for radioactivity. There is a large and increasing market need for efficient reagents for in vivo bacterial imaging. We aim to develop improved in vivo imaging and ex vivo analysis methods for the study of bacterial infectious diseases and host immune response to infections, to address the current need across the range of fields of infectious disease and vaccine research. A broad skill set is required in this rapidly advancing field, involving exposure to laboratory science, imaging technology, commercialisation of research and industrial processes. By bringing together an international network of leaders in the fields of molecular imaging, infectious disease, vaccine research and industry, we propose to address the current paucity of technology for imaging of bacteria in research animals. Novartis is a world leader in development of vaccines for infectious diseases, and will provide an industrial steer from the project outset. Through combining the various specialities of this IAPP, the proposed work programme will facilitate transfer of knowledge among project partners, promote the development and training of staff in both academia and industry, as well as providing the industry partner with new R&D tools.'